样式: 排序: IF: - GO 导出 标记为已读
-
HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-18 Stefano Giardino, Dirk-Jan Eikema, Brian Piepenbroek, Mattia Algeri, Mouhab Ayas, Maura Faraci, Abdelghani Tbakhi, Marco Zecca, Mohammed Essa, Bénédicte Neven, Yves Bertrand, Gaurav Kharya, Tatiana Bykova, Sarah Lawson, Mario Petrini, Alexander Mohseny, Fanny Rialland, Beki James, Anca Colita, Mony Fahd, Simone Cesaro, Ansgar Schulz, Katharina Kleinschmidt, Krzysztof Kałwak, Selim Corbacioglu, Carlo
Haploidentical stem cell transplantation (haplo-SCT) represents the main alternative for children with inherited bone marrow failure syndrome (I-BMF) lacking a matched donor. This retrospective study, conducted on behalf of the EBMT SAAWP and PDWP, aims to report the current outcomes of haplo-SCT in I-BMFs, comparing the different in vivo and ex vivo T-cell depletion approaches. One hundred and sixty-two
-
Favorable outcome of non‐myeloablative allogeneic transplantation in adult patients with severe sickle cell disease: A single center experience of 200 patients Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-16 Moussab Damlaj, Bader Alahmari, Ahmed Alaskar, Ayman Alhejazi, Husam Alsadi, Mazin Ahmed, Tahani Alanazi, Rasha Ahmed, Amani Alharbi, Inaam Shehabeddine, Afnan Alzaidi, Suha Alkhuraisat, Isam Mahassnah, Hamza Alquraan, Maybelle Ballili, Mohsen Alzahrani
Allogeneic hematopoietic stem cell transplant (HSCT) for adults with severe sickle cell disease (SCD) is potentially curative but not commonly utilized therapy due to complications such as graft failure (GF) and organ toxicity. Herein, we are reporting our long‐term outcome data of non‐myeloablative (NMA) HSCT in adults with severe SCD with emphasis on factors predicting event free survival (EFS).
-
Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta‐analysis Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-16 Bruno Almeida Costa, Thomaz Alexandre Costa, Sara Diaz Saravia, Nicole Felix, Carlyn Rose Tan, Neha Korde, Joshua Richter
-
Detection of signature double‐negative T cells is a predictive marker to identify autoimmune lymphoproliferative syndrome associated with FAS loss of function Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-14 Nina Eisenhauer, Maurizio Miano, Nora Naumann‐Bartsch, Jörg Leyh, Gianluca Dell'Orso, Michael Aigner, Gisela Fecker, Claas Hinze, Helmut Wittkowski, Heiko Bruns, Jakob Zierk, Markus Metzler, Peter D. Arkwright, Frederik Graw, Andreas Mackensen, Simon Völkl
The autoimmune lymphoproliferative syndrome (ALPS) is caused by defects in the FAS-dependent apoptosis leading to chronic lymphoproliferation, autoimmunity, chronic multilineage cytopenia, an increased risk for developing B cell lymphomas, and a characteristic accumulation of CD4/CD8-negative, T-cell receptor (TCR), αβ-positive T-cells (double-negative, DNT-cells).1, 2 The heterogeneous clinical phenotype
-
JAK inhibitor treatment‐resistant splenomegaly before transplantation in myelofibrosis: Splenectomy or radiotherapy? Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-14 Maria Chiara Finazzi, Ayalew Tefferi, Alessandro Rambaldi
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest.
-
A new chemotherapy‐free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-14 Hailong Tang, Weijing Jia, Shuangshuang Jia, Runan Dong, Shan Gao, Juan Feng, Hongjuan Dong, Hongtao Gu, Tao Zhang, Ruifeng Yuan, Xiangxiang Liu, Lu Cheng, Shuya Zhou, Guangxun Gao
In the era following the development of tyrosine kinase inhibitors (TKIs), the current standard of treatment for clinically fit patients with previously untreated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) is first- or second-generation TKIs combined with chemotherapy or corticosteroids, followed by allogeneic stem cell transplantation (allo-HCT). However, relapse still
-
A randomized double‐blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficiency anemia Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-13 Vanessa Short, Richard Allen, Christopher J. Earley, Huzefa Bahrain, Stella Rineer, Kiumarce Kashi, Jesse Gerb, Michael Auerbach
Restless legs syndrome (RLS) is a neurological disorder that can have a profound effect on sleep and quality of life. Idiopathic RLS is associated with brain iron insufficiency despite normal peripheral iron stores. There is, however, a five‐ to six‐fold increase in prevalence of RLS in patients with iron deficiency anemia (IDA). Several open‐label trials have demonstrated symptomatic improvement in
-
The latest insights into rare blood disorders: Diagnosis and treatment strategies Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-09 David J. Kuter, Spero R. Cataland, Catherine M. Broome, Cindy Neunert
Because immune‐mediated rare blood disorders are uncommon, healthcare providers often lack the knowledge and experience necessary to identify, diagnose, and treat them in accordance with best practices. As a result, there are significant gaps in care, including delays in diagnosis and suboptimal treatment. To ensure that more patients with these rare disorders are offered quality, evidence‐based care
-
Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-07 Mrinal M. Patnaik, Ayalew Tefferi
Disease OverviewChronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, characterized by prominent monocytosis and an inherent risk for leukemic transformation (~15%–20% over 3–5 years).DiagnosisNewly revised diagnostic criteria include sustained (>3 months) peripheral blood (PB) monocytosis
-
2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-07 Haris Ali, Andrea Bacigalupo
BackgroundAllogeneic hemopoietic stem cell transplantation (HSCT) currently remains the only curative treatment for patients with myelofibrosis (MF). Transplant related mortality (TRM) and relapse, remain two significant complications which need to be addressed.AimsThe aim of this manuscript is to review current available reports on changes which have recently occurred, to improve the outcome of MF
-
Changing hemostatic management in post‐partum hemorrhage Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-07 Agnès Rigouzzo, Pierre‐Antoine Froissant, Nicolas Louvet
Early and fast assessment of hemostasis during postpartum hemorrhage (PPH) is essential to allow early characterization of coagulopathy, estimate bleeding severity and improve outcome. During PPH, fibrinogen decrease occurs earlier than other coagulation factors deficiency and hypofibrinogenemia is an early marker of PPH severity of progression. With good evidence in the context of PPH, point‐of‐care
-
Mortality in adults with sickle cell disease: Results from the sickle cell disease implementation consortium (SCDIC) registry Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-07 Franklin Njoku, Norma Pugh, Donald Brambilla, Barbara Kroner, Nirmish Shah, Marsha Treadwell, Robert Gibson, Lewis L. Hsu, Victor R. Gordeuk, Jeffrey Glassberg, Jane S. Hankins, Abdullah Kutlar, Allison A. King, Julie Kanter
The cause of death in people affected by sickle cell disease (SCD) is often challenging to define as prior studies have used retrospective or administrative data for analysis. We used a prospective longitudinal registry to assess mortality and clinical co‐morbidities among subjects enrolled in the Sickle Cell Disease Implementation Consortium (SCDIC) registry. At enrollment, we collected the following
-
Results of a phase I trial with Haploidentical mbIL‐21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-06 Stefan O. Ciurea, Piyanuch Kongtim, Samer Srour, Julianne Chen, Doris Soebbing, Elizabeth Shpall, Katayoun Rezvani, Robin Nakkula, Aarohi Thakkar, Ella C. Troy, Alex A. Cash, Gregory Behbehani, Kai Cao, Jolie Schafer, Richard E. Champlin, Dean A. Lee
-
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-05 Garima Pandey, Lucia Mazzacurati, Tegan M. Rowsell, Nathan P. Horvat, Narmin E. Amin, Guolin Zhang, Afua A. Akuffo, Christelle M. Colin‐Leitzinger, Eric B. Haura, Andrew T. Kuykendall, Ling Zhang, Pearlie K. Epling‐Burnette, Gary W. Reuther
Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocytosis, and primary myelofibrosis, are clonal hematopoietic neoplasms driven by mutationally activated signaling by the JAK2 tyrosine kinase. Although JAK2 inhibitors can improve MPN patients' quality of life, they do not induce complete remission as disease‐driving cells persistently survive therapy. ERK activation
-
Myeloid neoplasm with <10% blasts and t(3;5)(q25.1;q34)/NPM::MLF1: A classification dilemma Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-05 Fnu Sameeta, Hong Fang, Wei Wang, Zhenya Tang, Sa A. Wang, Gokce A. Toruner, Xenia Parisi, Joseph D. Khoury, Ghayas Issa, Guillermo Garcia‐Manero, L. Jeffrey Medeiros, Guilin Tang, Sanam Loghavi
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest.
-
Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment—Annual updates in hematological malignancies Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-05 Xavier Troussard, Elsa Maître, Jérôme Paillassa
Hairy cell leukemia (HCL) and HCL-like disorders, including HCL variant (HCL-V) and splenic diffuse red pulp lymphoma (SDRPL), are a very heterogenous group of mature lymphoid B-cell disorders characterized by the identification of hairy cells, a specific genetic profile, a different clinical course and the need for appropriate treatment.
-
Treatment‐free remission in CML patients with additional chromosome abnormalities in the Philadelphia‐positive clone or variant Philadelphia translocations Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-04 Simone Claudiani, Lynette Chee, Fiona Fernando, Loretta Brown, Udayakumar M. Achandira, Afzal Khan, Kate Rothwell, Chloe Hayden, Ioannis Koutsavlis, Guy Hannah, Andrew Innes, Jane F. Apperley, Dragana Milojkovic
-
Leg ulcers are indicators of systemic dysfunction in individuals with sickle cell disease Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-03 Tiffany A. Jackson, Ashley J. Buscetta, Hasmin C. Ramirez, Vence L. Bonham, Caterina P. Minniti
-
Real‐world evidence: Long‐term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-02 Janet L. Kwiatkowski, Alexis A. Thompson, Fernando Tricta, Noemi Toiber Temin, Anna Rozova, Caroline Fradette, Sherif M. Badawy
Patients with sickle cell disease (SCD) and other anemias who receive blood transfusions are at risk of organ damage due to transfusional iron overload. Deferiprone is an iron chelator with a well‐established safety and efficacy profile that is indicated for the treatment of transfusional iron overload. Here, we report safety data from the large‐scale, retrospective Ferriprox® Total Care Registry,
-
Assessing hypercoagulability and VTE risk using thromboelastography and Khorana score in women with cancers receiving chemotherapy Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-01 Yousra Tera, Yoon Jin Suh, Karina Fainchtein, Anita Agrawal, Mihaela Mates, Maha Othman
-
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple myeloma Am. J. Hematol. (IF 12.8) Pub Date : 2024-03-01 Heinz Ludwig, Thomas Melchardt, Siegfried Sormann, Martin Schreder, Johannes Andel, Bernd Hartmann, Christoph Tinchon, Niklas Zojer, Eberhard Gunsilius, Klaus Podar, Alexander Egle, Wolfgang Willenbacher, Ewald Wöll, Reinhard Ruckser, Boris Bozic, Maria‐Theresa Krauth, Andreas Petzer, Clemens Schmitt, Sigrid Machherndl‐Spandl, Hermine Agis, Michael Fillitz, Song‐Yau Wang, August Zabernigg, Stefan Knop
-
Pituitary apoplexy in acute promyelocytic leukemia Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-29 Eitan Mirvis, Shwetha Sairam, Erika Vainieri, Francesca Tona, Catherine Hockings, Renuka Palanicawandar, Elisabet Nadal‐Melsio
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest.
-
Age barriers in allogeneic hematopoietic cell transplantation: Raising the silver curtain Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-28 Pashna N. Munshi, Shannon R. McCurdy
-
Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-26 Gordon J. Ruan, Saurabh Zanwar, Aishwarya Ravindran, Susan Schram, Jithma P. Abeykoon, Antonious Hazim, Jason R. Young, Mithun V. Shah, N. Nora Bennani, Liuyan Jiang, Diana Morlote, Karen L. Rech, Gaurav Goyal, Ronald S. Go
-
Report of IRF2BP1 as a novel partner of RARA in variant acute promyelocytic leukemia Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-27 Mei Jiang, Xuemei Wang, Min Yu, Shuling Jiang, Miao Hong, Yuru Zhou, Fei Li, Hongxing Liu, Zhanglin Zhang
-
Crizanlizumab and sickle cell disease: When should medications have their approval status revoked? Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-27 Jeremy W. Jacobs, Laura D. Stephens, David M. Chooljian, Deva Sharma, Brian D. Adkins, Garrett S. Booth
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest.
-
CALR‐mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-26 Laura Aubin, Rúben Vilas Boas, Rafael Daltro De Oliveira, Valoris Le Brun, Marion Divoux, Jérôme Rey, Olivier Mansier, Jean‐Christophe Ianotto, Cédric Pastoret, Anne Desmares, Anne Murati, Véronique de Mas, Suzanne Tavitian, François Girodon, Juliette Soret Dulphy, Nabih Maslah, Valérie Goncalves Monteiro, Françoise Boyer, Corentin Orvain, Dana Ranta, Émilie Cayssials, Lenaig Le Clech, Christophe Nicol
-
Erratum Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-26
Erratum to: Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial. Cooper N, Ghanima W, Vianelli N, Valcárcel D, Yavaşoğlu İ, Melikyan A, Ruiz EY, Haenig J, Somenzi O, Lee J, Clark J, Zhang Y, Zaja F. Sustained response off-treatment in eltrombopag-treated
-
From the eosinophil to a novel FGFR1 fusion gene Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-24 Kirsteen Harper, Gillian Horne, Mike Leach, Barbara J. Bain
A 41-year-old man was referred with a history of weight loss and fatigue after primary investigations showed a prominent eosinophilia (hemoglobin concentration 135 g/L, white cell count 20.6 × 109/L, neutrophils 9.1 × 109/L, eosinophils 5.36 × 109/L, and platelets 172 × 109/L). The blood film showed eosinophilia (top left) with left shift to eosinophil myelocytes (top center, top right), subtle neutrophil
-
Iron restriction in sickle cell disease: When less is more Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-24 Oswaldo L. Castro, Lucia De Franceschi, Tomas Ganz, Julie Kanter, Gregory J. Kato, Sant‐Rayn Pasricha, Stefano Rivella, John C. Wood
Primum non nocere! Can iron deficiency, an abnormality that causes anemia, benefit people with sickle cell disease (SCD) who already have an anemia? The published literature we review appears to answer this question in the affirmative: basic science considerations, animal model experiments, and noncontrolled clinical observations all suggest a therapeutic potential of iron restriction in SCD. This
-
Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trial Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-24 Issa F. Khouri, Kamal Alzahrani, Hagop Kantarjian, Denái R. Milton, Alison M. Gulbis, Koji Sasaki, Nitin Jain, Nicholas J. Short, Tapan Kadia, May Daher, Hind Rafei, Jin S. Im, David Marin, Amanda L. Olson, Uday Popat, Muzaffar Qazilbash, Jeremy Ramdial, Gabriela Rondon, Samer Srour, Partow Kebriaei, Elizabeth Shpall, Richard Champlin, Elias J. Jabbour
-
Neutrophilic leukemoid reaction or chronic neutrophilic leukemia—not always so simple Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-24 Yorick Sandberg, Leo M. Budel, Barbara J. Bain
An 85-year-old man with a history of hypertension and cerebrovascular disease was admitted with anemia (hemoglobin concentration 100 g/L) and leukocytosis (white blood cell count 68.9 × 109/L; neutrophils 88%, 60.6 × 109/L). Physical examination was unremarkable. His blood film showed toxic granulation and Döhle bodies, but no blast cells or neutrophil precursors (top left, May-Grünwald-Giemsa (MGG) × 100
-
The impact of sex on platelet responses to aspirin in patients with peripheral artery disease Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-24 Sasha P. Suarez Ferreira, Ryan P. Hall, Katherine Morrow, Shiv Patel, Ivy Lee, Fanah Hagos, Nikolaos Zacharias, Kellie Machlus, Anahita Dua
-
NPM1‐mutated myeloid neoplasm with low percentage of blasts Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-24 Brunangelo Falini, Patrizia Chiusolo, Luana Fianchi, Livio Pagano
CONFLICT OF INTEREST STATEMENT B.F. holds a patent on NPM1 mutants (number 102004901256449). The remaining authors declare no competing financial interests.
-
Risk models in myelofibrosis—the past, present, and future Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-23 Ayalew Tefferi, Alessandro M. Vannucchi
-
Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T‐cell lymphomas Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-23 Eric Mou, Sebastian Fernandez‐Pol, Shufeng Li, Kerri E. Rieger, Roberto Novoa, Carlos J. Suarez, Rebekah Wieland, Wen‐Kai Weng, Youn H. Kim, Michael S. Khodadoust
Cytotoxic cutaneous T-cell lymphomas (CCTCLs) are uncommon neoplasms involving skin-tropic T cells expressing cytotoxic markers (e.g. TIA-1, granzyme, and/or perforin). They are comprised of both standalone entities and subsets therein, as defined by the World Health Organization (WHO) fifth edition.1 In addition, we refer to CCTCLs that do not otherwise fit a specific category as cytotoxic cutaneous
-
The triple A model (age, absolute neutrophil count, absolute lymphocyte count‐AAA) predicts survival and thrombosis in polycythemia vera Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-23 Ivan Krecak, Danijela Lekovic, Isidora Arsenovic, Hrvoje Holik, Ivan Zekanovic, Martina Moric Peric, Marko Lucijanic
BCR::ABL1-negative chronic myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis are characterized by constitutive activation of the JAK-STAT signaling pathway caused by mutations in the Janus Kinase 2 (JAK2), carelticulin, or thrombopoetin receptor genes. These neoplasms share persistent chronic inflammatory state and high cardiovascular risk
-
Hematoidin crystals in an ectopic pregnancy patient with septic and hemorrhagic shock Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-22 Mei Yang, Ting Li, Yun Zhang
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest.
-
Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-22 Nicola Polverelli, Edouard F. Bonneville, Liesbeth C. de Wreede, Linda Koster, Nicolaus Martin Kröger, Thomas Schroeder, Régis Peffault de Latour, Jakob Passweg, Katja Sockel, Annoek E. C. Broers, Andrew Clark, Peter Dreger, Didier Blaise, Ibrahim Yakoub‐Agha, Soeren Lykke Petersen, Jürgen Finke, Patrice Chevallier, Grzegorz Helbig, Werner Rabitsch, Simona Sammassimo, Luca Arcaini, Domenico Russo,
-
COVID-19 vaccine safety and immunogenicity in patients with cold agglutinin disease receiving concomitant sutimlimab Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-22 Bruno Fattizzo, Alexander Röth, Catherine M. Broome, Umer Khan, Marek Wardęcki, Matias Cordoba, Wilma Barcellini
-
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-21 Corentin Orvain, Naveed Ali, Megan Othus, Eduardo Rodríguez‐Arbolí, Filippo Milano, Calvin M. Le, Brenda M. Sandmaier, Bart L. Scott, Frederick R. Appelbaum, Roland B. Walter
Multiparameter flow cytometry (MFC) measurable residual disease (MRD) before allogeneic hematopoietic cell transplantation (HCT) independently predicts poor outcomes in acute myeloid leukemia (AML). Conversely, its prognostic value in the newly defined disease entity, myelodysplastic neoplasm (MDS)/AML is unknown. To assess the relationship between disease type, pre‐HCT MRD, and post‐HCT outcomes,
-
Six‐week low‐molecular‐weight heparin versus 12‐week warfarin for calf deep vein thrombosis: A randomized, prospective, open‐label study Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-20 Michelangelo Sartori, Matteo Iotti, Giuseppe Camporese, Sergio Siragusa, Davide Imberti, Eugenio Bucherini, Sara Corradini, Walter Ageno, Paolo Prandoni, Angelo Ghirarduzzi
-
Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-20 Naseema Gangat, Ayalew Tefferi
-
Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-15 Nico Gagelmann, Gabriela S. Hobbs, Edoardo Campodonico, Grzegorz Helbig, Polona Novak, Thomas Schroeder, Artur Schneider, Christina Rautenberg, Hans Christian Reinhardt, Linette Bosques, Michael Heuser, Victoria Panagiota, Felicitas Thol, Carmelo Gurnari, Jaroslaw P. Maciejewski, Fabio Ciceri, Kristin Rathje, Marie Robin, Simona Pagliuca, Marie-Thérèse Rubio, Vanderson Rocha, Vaneuza Funke, Nelson
-
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-15 Alex Bataller, Courtney D. DiNardo, Alexandre Bazinet, Naval G. Daver, Abhishek Maiti, Gautam Borthakur, Nicholas Short, Koji Sasaki, Elias J. Jabbour, Ghayas C. Issa, Naveen Pemmaraju, Musa Yilmaz, Guillermo Montalban-Bravo, Sanam Loghavi, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia
-
Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-15 Adam S. Kittai, Ying Hang, Seema A. Bhat, Abi Clark, Michael Grever, Joanna M. Rhodes, Melyssa Roberts, Kerry A. Rogers, Anna Teschemaker, Maria Munoz-Sagastibelza, Jennifer A. Woyach, Jacqueline C. Barrientos
-
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-13 Morag Griffin, Richard Kelly, Isabelle Brindel, Lynda Maafa, Roochi Trikha, Petra Muus, Talha Munir, Abraham Mullasseril Varghese, Lindsay Mitchell, Sateesh Nagumantry, Shreyans Gandhi, Alex Pike, Austin G. Kulasekararaj, Regis Peffault de Latour
-
Cancer-associated non-bacterial thrombotic endocarditis—Clinical series from a single institution Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-13 Patryk Patrzalek, Waldemar E. Wysokinski, Reto D. Kurmann, Damon Houghton, David Hodge, Wiktoria Kuczmik, Kyle W. Klarich, Ewa M. Wysokinska
-
Postgraduate Institute of India (PGI) textbook of laboratory and clinical hematology. By Koyamangalath Krishnan (Ed.), Mumbai, India: Bhalani Publishing House. 2024. pp. 3244. ISBN: 9789381496763 Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-13 Rajiv K. Pruthi
CONFLICT OF INTEREST STATEMENT Author declares no conflict of interest.
-
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-11 Francesco Autore, Andrea Visentin, Marina Deodato, Candida Vitale, Eugenio Galli, Alberto Fresa, Rita Fazzi, Alessandro Sanna, Jacopo Olivieri, Ilaria Scortechini, Maria Ilaria Del Principe, Paolo Sportoletti, Luana Schiattone, Nilla Maschio, Davide Facchinelli, Francesco Marchesi, Marta Coscia, Alessandra Tedeschi, Livio Trentin, Idanna Innocenti, Anna Candoni, Alessandro Busca, Livio Pagano, Luca
-
Long-term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-11 Mary Eapen, Jianqun Kou, Martin Andreansky, Monica Bhatia, Joel Brochstein, Sonali Chaudhury, Ann E. Haight, Hilary Haines, David Jacobsohn, Jennifer Jaroscak, Kimberly A. Kasow, Lakshmanan Krishnamurti, John E. Levine, Kathryn Leung, David Margolis, Lolie C. Yu, Mary M. Horowitz, Naynesh Kamani, Mark C. Walters, Shalini Shenoy
HLA-matched sibling donor transplantation accounts for the majority of transplants performed for sickle cell disease (SCD). However, only about 18% of patients in the United States with SCD will have unaffected human leukocyte antigen (HLA)-matched siblings or one with sickle trait, limiting applicability. A Blood and Marrow Transplant Clinical Trials Network phase II trial of HLA-matched unrelated
-
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-11 Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Wei Li, Qian Jiang, Xiuli Wang, Jinwen Huang, Huanling Zhu, Linhua Yang, Xin Du, Fei Li, Ruixiang Xia, Feng Zhang, Jianda Hu, Yan Li, Yu Hu, Jing Liu, Chenghao Jin, Kai Sun, Zeping Zhou, Liqing Wu, Hewen Yin, Shanshan Suo, Wenjuan Yu, Jie Jin
-
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-11 Yasmin Abaza, Eric S. Winer, Guru Subramanian Guru Murthy, Rory M. Shallis, Andrew H. Matthews, Talha Badar, Emily M. Geramita, Vamsi K. Kota, Alok Swaroop, Peter Doukas, Danielle Bradshaw, Irene B. Helenowski, Yingzhe Liu, Hui Zhang, Annie Im, Mark R. Litzow, Alexander E. Perl, Ehab Atallah, Jessica K. Altman
-
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-11 Keith W. Pratz, Brian A. Jonas, Vinod Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Hartmut Döhner, Christian Récher, Walter Fiedler, Kazuhito Yamamoto, Jianxiang Wang, Sung-Soo Yoon, Ofir Wolach, Su-Peng Yeh, Brian Leber, Jordi Esteve, Jiri Mayer, Kimmo Porkka, Árpád Illés, Roberto M. Lemoli, Mehmet Turgut, Grace Ku, Catherine Miller, Ying Zhou, Meng Zhang, Brenda Chyla, Jalaja Potluri, Courtney
-
Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-08 Alexandra Power-Hays, George A. Tomlinson, Leon Tshilolo, Brígida Santos, Thomas N. Williams, Peter Olupot-Olupot, Luke R. Smart, Banu Aygun, Adam Lane, Susan E. Stuber, Teresa Latham, Russell E. Ware
-
New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-08 Naseema Gangat, Ayalew Tefferi
-
Donor germ-line variants associate with outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromes Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-09 Paul L. Auer, Manzur Farazi, Tao Zhang, Jing Dong, Yung-Tsi Bolon, Stephen R. Spellman, Wael Saber
-
Transcranial doppler velocity in iron-deficient Nigerian children with sickle cell anemia Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-07 Shehu Umar Abdullahi, Surayya Sunusi, Hauwa Aminu, Rashida Umar, Mohammed Sani Abba, Binta W. Jibir, Saifuddeen Sani, Safiya Gambo, Halima Bello-Manga, Najibah A. Galadanci, Brittany Covert Greene, Adetola A. Kassim, Lori C. Jordan, Muktar H. Aliyu, Mark Rodeghier, Michael R. DeBaun, Emmanuel J. Volanakis
-
Advances towards genome-based acute myeloid leukemia classification: A comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus Classification Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-06 Xue Chen, Lili Yuan, Yang Zhang, Fang Wang, Xiaoli Ma, Jiancheng Fang, Panxiang Cao, Yijun Liu, Zhixiu Liu, Ming Liu, Jiaqi Chen, Xiaosu Zhou, Mingyue Liu, David Jin, Tong Wang, Peihua Lu, Hongxing Liu
-
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study Am. J. Hematol. (IF 12.8) Pub Date : 2024-02-05 Sairah Ahmed, Qaiser Bashir, Roland L. Bassett, Fauzia Ullah, Fleur Aung, Benigno C. Valdez, Amin M. Alousi, Chitra Hosing, Partow Kebriaei, Issa Khouri, David Marin, Yago Nieto, Amanda Olson, Betul Oran, Muzaffar H. Qazilbash, Katayoun Rezvani, Rohtesh Mehta, Elizabeth J. Shpall, Stefan Ciurea, Borje S. Andersson, Richard E. Champlin, Uday R. Popat